Articles

RSS

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced recently that Peter Green has resigned as Chairman of the Board and a Director of Patheon Inc. effective yesterday.

Peter joined the Board in 1996 and has held the position of Chairman since that time. The Board would like to thank Peter for his 13 years of service and wishes him well in his future endeavors.

The Board has appointed Claudio F. Bussandri, who joined the Board in March 2008, as the Corporation's new Chairman. Mr. Bussandri is the retired President and CEO of McKesson Canada, a diversified healthcare services company, where he served from 1995 to 2007. Prior to that, Mr. Bussandri was President and CEO of Lantic Sugar Limited, a Canadian sugar refiner, from 1987 to 1995. He also served as Executive Chairman of Lantic's U.S. subsidiary, Refined Sugar Inc. (RSI), and Executive Chairman of Lantic's Barbados sugar trading company. Mr. Bussandri has also held senior positions at Nabisco Brands Limited of Canada from 1974 to 1987, including President of the Food Service Division and held management positions with Gillette of Canada from 1969 to 1974. Currently, Mr. Bussandri is Vice-Chairman of the Board of the McGill University Health Centre ("MUHC"), and is Chairman of MUHC's Human Resource Committee. He was previously an Executive Board member and former Chairman of the Canadian Association for Pharmacy Distribution Management. Mr. Bussandri received a Bachelor of Engineering (Mechanical) with honours from McGill University and an M.B.A. from the same university.

About Patheon
Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard cpsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon's integrated development and manufacturing network of 10 facilities, and 7 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

SOURCE: Patheon Inc.